Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Notes Payables (2016 - 2018)

Tg Therapeutics has reported Notes Payables over the past 3 years, most recently at $67000.0 for Q4 2018.

  • Quarterly results put Notes Payables at $67000.0 for Q4 2018, down 47.66% from a year ago — trailing twelve months through Dec 2018 was $67000.0 (down 47.66% YoY), and the annual figure for FY2018 was $67000.0, down 47.66%.
  • Notes Payables for Q4 2018 was $67000.0 at Tg Therapeutics, down from $91000.0 in the prior quarter.
  • Over the last five years, Notes Payables for TGTX hit a ceiling of $224000.0 in Q1 2018 and a floor of $67000.0 in Q4 2018.
  • Median Notes Payables over the past 3 years was $140284.0 (2017), compared with a mean of $138238.6.
  • Biggest five-year swings in Notes Payables: surged 85.84% in 2017 and later crashed 50.04% in 2018.
  • Tg Therapeutics' Notes Payables stood at $68875.0 in 2016, then surged by 85.84% to $128000.0 in 2017, then crashed by 47.66% to $67000.0 in 2018.
  • The last three reported values for Notes Payables were $67000.0 (Q4 2018), $91000.0 (Q3 2018), and $210000.0 (Q2 2018) per Business Quant data.